Antipodes Awarded 2026 Morningstar Fund Manager of the Year

Antipodes Partners has been awarded Australia’s Overall Fund Manager of the Year at the 2026 Morningstar Awards for Investing Excellence in Australia. 

Established in 2015, Antipodes has grown to now manage over $20 billion across five independent investment teams across the Antipodes and Maple-Brown Abbott brands: Global Equities, Global Credit, Global Listed Infrastructure, Australian Small Companies and Australian Value Equities. Each team operates with its own distinct investment approach, yet shares a common commitment to genuinely active management and to delivering strong outcomes for clients. 

Along with the coveted 2026 Overall Fund Manager of the Year award, Antipodes was also recognised in three other categories at the awards ceremony, held in Sydney on 19 February 2026, including: 

• 2025 Fund Manager of the Year – Australian Equities – Small Cap (Maple-Brown Abbott Australian Small Companies Fund)
• Finalist, 2025 Fund Manager of the Year – Global Equities (Antipodes Global Strategies)
• Finalist, 2025 Fund Manager of the Year – Infrastructure (Maple-Brown Abbott Global Listed Infrastructure Fund)

Antipodes Managing Director and CEO, Andrew Findlay, extended Antipodes’ gratitude to Morningstar for the recognition.  

“To be recognised as Overall Fund Manager of the Year speaks to the quality and diversity of our growing investment platform, and is a wonderful reward for over a decade of hard work. 

It is a particular honour because we saw our talented teams nominated across multiple award categories – Global Equities, Global Listed Infrastructure, and Australian Small Companies. That breadth of recognition is a testament to the outstanding performance of each of those teams, and frankly, the award belongs to every one of them.” 

Antipodes founder and Global Equities CIO, Jacob Mitchell said: “Since establishing Antipodes in 2015, our focus has always been on delivering a smoother investment journey – finding high-quality businesses trading at attractive valuations across the world. I’m proud of our outstanding team and differentiated investment approach, which has endured through numerous market cycles.” 

Maple-Brown Abbott Australian Small Companies Co-Portfolio Manager, Phillip Hudak said: “Being recognised by Morningstar in the Australian Equities – Small Cap category is both humbling and a tremendous honour. At Maple-Brown Abbott, we believe that a rigorous focus on earnings quality, business sustainability and disciplined risk management is the foundation for delivering more consistent returns with lower volatility than the broader Australian small companies market. We believe this recognition is a reflection of that commitment.” Phillip Hudak, Co-Portfolio Manager, Australian Small Companies. 

The Morningstar Awards for Investing Excellence in Australia recognise funds and asset managers that have served investors well over the long term and that Morningstar’s manager research team believes will be able to deliver strong risk-adjusted returns over time.

For more information about Antipodes visit https://antipodes.com/.

Important Information:

Morningstar Awards 2026 ©. Morningstar, Inc. All Rights Reserved. Awarded to Antipodes Partners for Overall Fund Manager of the Year, Finalist, Fund Manager of the Year – Global Equities, Australia. Awarded to Maple-Brown Abbott for Fund Manager of the Year – Domestic Equities – Small Cap, Finalist Fund Manager of the Year – Infrastructure, Australia.

This communication has been prepared by Antipodes Partners Limited (‘Antipodes’) (ABN 29 602 042 035, AFSL 481 580) to provide you with general information only. In preparing this communication, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Antipodes nor any of its related parties, their employees or directors, provide and warranty of accuracy or reliability in relation to such information or accepts any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. The Funds’ Target Market Determinations are available on relevant fund pages on the Antipodes website and/or the Maple-Brown Abbott website.